# Dose-Ranging Study of BAY 59-7939 on the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement

> **NCT00398905** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 726 (actual)

## Conditions studied

- Venous Thromboembolism

## Interventions

- **DRUG:** Rivaroxaban (Xarelto, BAY59-7939)
- **DRUG:** Rivaroxaban (Xarelto, BAY59-7939)
- **DRUG:** Rivaroxaban (Xarelto, BAY59-7939)
- **DRUG:** Rivaroxaban (Xarelto, BAY59-7939)
- **DRUG:** Rivaroxaban (Xarelto, BAY59-7939)
- **DRUG:** Enoxaparin

## Key facts

- **NCT ID:** NCT00398905
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** —
- **Final completion:** 2004-09
- **Target enrollment:** 726 (ACTUAL)
- **Last updated:** 2009-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00398905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00398905, "Dose-Ranging Study of BAY 59-7939 on the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00398905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*